UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

Annals of oncology, 2021-05, Vol.32 (5), p.631-641

2021

Volltextzugriff (PDF)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

Annals of oncology, 2019-08, Vol.30 (8), p.1311-1320

2019

Volltextzugriff (PDF)

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Nature communications, 2018-08, Vol.9 (1), p.3196-15, Article 3196

2018

Volltextzugriff (PDF)

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Volltextzugriff (PDF)

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

1330 Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S114-S114

2016

Volltextzugriff (PDF)

IBS15.01 Current Status of IO in Lung Cancer

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S105-S106

Gettinger, S.

2019

Volltextzugriff (PDF)

CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii544-viii545

2018

Volltextzugriff (PDF)

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Annals of oncology, 2018-12, Vol.29, p.x43-x43

2018

Volltextzugriff (PDF)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

ESMO open, 2023-04, Vol.8 (2), p.101160-101160, Article 101160

2023

Volltextzugriff (PDF)

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S32-S33

2014

Volltextzugriff (PDF)

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S34-S35

2014

Volltextzugriff (PDF)

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

Annals of oncology, 2018-10, Vol.29, p.viii746-viii746

2018

Volltextzugriff (PDF)

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S32-S32

2014

Volltextzugriff (PDF)

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S39-S40

2014

Volltextzugriff (PDF)

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

European journal of cancer (1990), 2015-09, Vol.51, p.S602-S602

2015

Volltextzugriff (PDF)

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S31-S31

2014

Volltextzugriff (PDF)

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S2-S2

2014

Volltextzugriff (PDF)

Association Between Neighborhood Context and Psychotropic Polypharmacy Use Among High-Need Children

Psychiatric services (Washington, D.C.), 2024-09

2024

Volltextzugriff (PDF)

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2027-2039

2018

Volltextzugriff (PDF)

EP08.02-125 Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S462-S463

2022

Volltextzugriff (PDF)

3:10 PM Abstract No. 44 Thermal ablation and stereotactic radiation therapy for stage I NSCLC: contemporary trends and outcomes from the National Cancer Database

Journal of vascular and interventional radiology, 2018-04, Vol.29 (4), p.S23-S23

2018

Volltextzugriff (PDF)

Current Status of IO in Lung Cancer: IBS15.01

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S105-S106

Gettinger, S

2019

Volltextzugriff (PDF)

3:18 PM Abstract No. 148 Current United States nationwide utilization of thermal ablation for lung cancer

Journal of vascular and interventional radiology, 2020-03, Vol.31 (3), p.S70-S70

2020

Volltextzugriff (PDF)

1 – 25 von 816

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(660)
Mit Volltextzugriff
(654)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(245)
Life Sciences & Biomedicine
(217)
Humans
(169)
Female
(106)
Oncology
(104)
Male
(97)
Aged
(70)
Middle Aged
(68)
Biological And Medical Sciences
(66)
Lung Neoplasms - Drug Therapy
(56)
Animals
(54)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(53)
Social Sciences
(53)
Adult
(50)
Lung Cancer
(39)
Lung Neoplasms - Pathology
(39)
Immunotherapy
(38)
Fundamental And Applied Biological Sciences. Psychology
(36)
Aged, 80 And Over
(35)
Psychology
(34)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

1330 Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

IBS15.01 Current Status of IO in Lung Cancer

CheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E)

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Association Between Neighborhood Context and Psychotropic Polypharmacy Use Among High-Need Children

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

EP08.02-125 Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer

3:10 PM Abstract No. 44 Thermal ablation and stereotactic radiation therapy for stage I NSCLC: contemporary trends and outcomes from the National Cancer Database

Current Status of IO in Lung Cancer: IBS15.01

3:18 PM Abstract No. 148 Current United States nationwide utilization of thermal ablation for lung cancer

Suchergebnisse filtern